Michael Freeman
Stock Analyst at Raymond James
(2.87)
# 1,493
Out of 5,170 analysts
5
Total ratings
80%
Success rate
28.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Freeman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Assumes: Outperform | $14 | $12.12 | +15.51% | 1 | Jun 11, 2025 | |
| TECX Tectonic Therapeutic | Reinstates: Outperform | $76 | $30.83 | +146.51% | 1 | Jun 11, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $37 | $17.80 | +107.87% | 1 | Jun 11, 2025 | |
| IRON Disc Medicine | Reinstates: Strong Buy | $89 | $59.17 | +50.41% | 1 | Jun 11, 2025 | |
| BHC Bausch Health Companies | Initiates: Market Perform | $8 | $5.03 | +59.05% | 1 | Jul 10, 2024 |
Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $12.12
Upside: +15.51%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $30.83
Upside: +146.51%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $17.80
Upside: +107.87%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $59.17
Upside: +50.41%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $5.03
Upside: +59.05%